PFO
ABBV icon

Pathstone Family Office’s AbbVie ABBV Stock Holding History

Pathstone Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$25.3M Buy
169,603
+113,959
+205% +$16.7M 0.19% 84
2023
Q2 		$7.1M Buy
55,644
+3,769
+7% +$553K 0.1% 137
2023
Q1 		$8.14M Sell
51,875
-114,715
-69% -$17.5M 0.13% 105
2022
Q4 		$24.5M Buy
166,590
+41,550
+33% +$6.37M 0.21% 84
2022
Q3 		$16.9M Buy
125,040
+86,483
+224% +$12.4M 0.15% 87
2022
Q2 		$5.91M Buy
38,557
+18,605
+93% +$2.84M 0.13% 94
2022
Q1 		$3.31M Sell
19,952
-1,454
-7% -$211K 0.08% 125
2021
Q4 		$2.9M Buy
21,406
+1,159
+6% +$137K 0.07% 142
2021
Q3 		$2.18M Buy
20,247
+736
+4% +$84.1K 0.06% 153
2021
Q2 		$2.2M Buy
19,511
+4,709
+32% +$530K 0.07% 151
2021
Q1 		$1.6M Buy
14,802
+5,536
+60% +$592K 0.05% 147
2020
Q4 		$993K Buy
9,266
+3,837
+71% +$369K 0.04% 121
2020
Q3 		$475K Buy
5,429
+89
+2% +$8.38K 0.05% 117
2020
Q2 		$526K Buy
5,340
+2,304
+76% +$203K 0.06% 102
2020
Q1 		$233K Buy
3,036
+229
+8% +$19.5K 0.03% 154
2019
Q4 		$2.49M Buy
2,807
+72
+3% +$5.98K 0.03% 141
2019
Q3 		$207K Sell
2,735
-5,429
-66% -$372K 0.03% 143
2019
Q2 		$595K Buy
8,164
+1,282
+19% +$101K 0.07% 118
2019
Q1 		$555K Buy
+6,882
New +$563K 0.07% 108
2018
Q2 		– Sell
-362
Closed -$34K – 151
2018
Q1 		$34K Buy
+362
New +$39.8K 0.02% 126
2017
Q3 		– Sell
-4,015
Closed -$291K – 170
2017
Q2 		$291K Sell
4,015
-137
-3% -$9.21K 0.12% 75
2017
Q1 		$271K Sell
4,152
-472
-10% -$29.7K 0.15% 76
2016
Q4 		$289K Buy
4,624
+4,528
+4,717% +$276K 0.18% 67
2016
Q3 		$6K Sell
96
-88
-48% -$5.7K 0.01% 155
2016
Q2 		$11K Hold
184
– – 0.01% 128
2016
Q1 		$10K Buy
+184
New +$10.3K 0.02% 114
2015
Q4 		– Sell
-80
Closed -$4K – 90
2015
Q3 		$4K Buy
+80
New +$5.21K 0.01% 128

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pathstone Family Office's ABBV Position: Q3 2023 in Review

Pathstone Family Office increased its AbbVie (ABBV) stake by 205% in Q3 2023, buying an estimated $16.7M and bringing the position to 169,603 shares worth $25.3M. The position accounts for 0.19% of the portfolio, ranked #84.

Pathstone Family Office first reported a position in ABBV in Q3 2015 and has held it in 27 quarters since. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Pathstone Family Office held 169,603 shares of AbbVie worth $25.3M as of Q3 2023.
  • Pathstone Family Office bought 113,959 AbbVie shares in Q3 2023, an estimated $16.7M.
  • AbbVie made up 0.19% of Pathstone Family Office's portfolio in Q3 2023, its #84 holding.
  • Pathstone Family Office first reported a position in AbbVie in Q3 2015 and has held it in 27 quarters since.
  • 3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.